Aurobindo Pharma Analyst Review 2027: Record Quarter Lifts Targets Near ₹2,110
- November 20, 2026
- Posted by: Kunal Singla
- Category: Market
Aurobindo Pharma Stock Snapshot (19 Nov 2026)
- Current Market Price (CMP): ₹1,805.70
- 52-Week High / Low: ₹1,859.90 / ₹1,106
- Market Capitalisation: ₹1,03,900 crore
- P/E Ratio vs Industry P/E: 26.1 vs 40.1
- Latest Quarter (Q2 FY27) Revenue: About ₹10,432 crore
- Latest Quarter (Q2 FY27) Net Profit: About ₹1,124 crore
Quick Answer: The Aurobindo Pharma analyst review 2027 shows a record quarter, with Q2 FY27 consolidated net profit up about 33% to about ₹1,124 crore and EBITDA up about 29%. Geojit set a target of ₹2,111 and Motilal Oswal ₹2,110, both with Buy ratings, while Prabhudas Lilladher rates it Hold at ₹1,775. The stock closed at ₹1,805.70 on 19 November 2026, close to its 52-week high, so the Aurobindo Pharma share price target 2027 range points to about 17% upside at the top.
The Aurobindo Pharma analyst review 2027 covers one of India’s largest generic drug makers, based in Hyderabad, which sells pills, injectables and biosimilars in the US, Europe and emerging markets. Readers searching for an Aurobindo Pharma share price target 2027 want to know whether the rally to near record levels still leaves room for gains.
Aurobindo Pharma closed at ₹1,805.70 on 19 November 2026, about 3% below its 52-week high of ₹1,859.90 and about 63% above its low of ₹1,106. This Aurobindo Pharma analyst review 2027 sets out what brokerages expect and what shapes the Aurobindo Pharma stock outlook 2027.
Click Here – Get Free Investment Predictions
What Analysts Say in the Aurobindo Pharma Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| Geojit Financial Services | Buy | ₹2,111 | November 2026 |
| Motilal Oswal | Buy | ₹2,110 | November 2026 |
| Prabhudas Lilladher | Hold | ₹1,775 | November 2026 |
Geojit values the stock at 22 times FY28 adjusted EPS and expects EBITDA margin to rise from 20.4% in FY26 to 21.4% in FY27 and 21.8% in FY28. Motilal Oswal values it at 21 times 12-month forward earnings and expects about 20% earnings growth a year, led by Europe, Lannett and the Penicillin G project.
Prabhudas Lilladher sees multiple growth drivers but keeps a Hold rating with a target slightly below the current price. In this Aurobindo Pharma analyst review 2027, the average of the three brokerage targets is about ₹1,999, about 11% above the market price.
Q2 FY27 Results in the Aurobindo Pharma Analyst Review 2027
| Metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue | About ₹10,432 crore | About ₹8,406 crore | Up about 24% |
| EBITDA | About ₹2,324 crore | About ₹1,799 crore | Up about 29% |
| EBITDA margin | About 22.3% | About 21.4% | Higher |
| Net profit | About ₹1,124 crore | About ₹848 crore | Up about 33% |
| Q1 FY27 net profit | About ₹1,032 crore | Not applicable | Up about 9% QoQ |
Motilal Oswal called the quarter an operational beat driven by broad-based formulation growth. The consolidation of Lannett in the US added to sales, while Europe kept growing at a double-digit pace.
Net profit crossed ₹1,100 crore for the first time in a quarter. In this Aurobindo Pharma analyst review 2027, the key point is that margin rose even as the company spent on new plants and biosimilar development.
Management reiterated FY27 guidance of double-digit revenue growth, an EBITDA margin above 21% and absolute EBITDA above ₹8,000 crore, and said FY28 should be significantly stronger than FY27.
How Aurobindo Pharma Makes Money
Aurobindo sells generic and speciality medicines across several regions and businesses.
- US formulations: oral generics, now including Lannett, the largest revenue pool.
- Eugia injectables: sterile products expected to cross 500 million dollars in FY27 revenue.
- Europe: a large generics business with double-digit growth expected in FY27.
- Growth markets and APIs: emerging markets and bulk drug sales.
- Biosimilars: early sales in Europe and the UK, with US filings planned.
FY26 revenue was about ₹34,145 crore with net profit of about ₹3,503 crore, after ₹32,346 crore and ₹3,484 crore in FY25. Operating cash flow rose to about ₹5,526 crore in FY26 from about ₹3,925 crore, which strengthens this Aurobindo Pharma analyst review 2027.
The company plans initial US FDA filings for omalizumab, denosumab and bevacizumab biosimilars. The Penicillin G plant, built under a government incentive scheme to cut import dependence, is already running at a modest positive EBITDA before scheme benefits.
Aurobindo is one of the larger weights in the Nifty Pharma index. Its valuation has long been lower than many peers because of US regulatory issues at some plants, which is part of why analysts see room for rerating if compliance stays clean.
Growth Triggers in the Aurobindo Pharma Analyst Review 2027
- Record earnings: net profit up about 33% in Q2 FY27.
- Lannett: full-year consolidation benefits expected in FY28.
- Biosimilars: US filings for three products and launches in Europe.
- Penicillin G: a domestic supply project with incentive support.
- Clear guidance: EBITDA above ₹8,000 crore in FY27, relevant to any Aurobindo Pharma share price target 2027 view.
Key Risks in the Aurobindo Pharma Analyst Review 2027
- US FDA risk: inspection findings at plants can delay approvals.
- US price erosion: generic prices fall as competition rises.
- Biosimilar execution: approvals and launches can take longer than planned.
- Currency: a stronger rupee would reduce export earnings.
- Price near targets: the stock is above the Hold target, a key point in the Aurobindo Pharma analyst review 2027.
Compare Aurobindo Pharma With Other Pharma Stocks on the Univest Screener
Aurobindo Pharma Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (19 Nov 2026) | ₹1,805.70 |
| 52-Week High / Low | ₹1,859.90 / ₹1,106 |
| Market Capitalisation | About ₹1,03,900 crore |
| P/E (TTM) | About 26.1 |
| Industry P/E | About 40.1 |
| Return on Equity | About 10.1% |
| Debt to Equity | 0.22 |
| Named Target Range | ₹1,775 to ₹2,111 |
The P/E of about 26 is well below the industry level of about 40, even after the rally. In this Aurobindo Pharma analyst review 2027, the discount reflects past regulatory issues and lower return on equity, while brokerages argue faster earnings growth can narrow the gap.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 51.82% | 51.88% | Up 0.06 pts |
| Foreign Investors (FII) | 14.21% | 17.41% | Up 3.20 pts |
| Domestic Institutions (DII) | 27.60% | 24.42% | Down 3.18 pts |
| Public | 6.38% | 6.29% | Down 0.09 pts |
RPR Sons Advisors holds 33.54% within the promoter group. Foreign investors raised their stake by about 3.2 points while domestic institutions cut by a similar amount, which the Aurobindo Pharma analyst review 2027 reads as a handover from local funds to overseas buyers during the rally.
What to Watch After the Aurobindo Pharma Analyst Review 2027
- Margins: whether EBITDA margin stays above 21%.
- US FDA: outcomes of plant inspections.
- Biosimilar filings: progress on the three US submissions.
- Europe growth: delivery of double-digit growth.
- Target revisions: any change to the Aurobindo Pharma share price target 2027 after Q3.
Final Word on the Aurobindo Pharma Analyst Review 2027
The Aurobindo Pharma analyst review 2027 shows record earnings, rising margins and clear guidance, with new growth engines in biosimilars, injectables and Penicillin G. The stock trades near its high but still at a discount to the sector.
The Aurobindo Pharma stock outlook 2027 depends on US regulatory outcomes, Lannett integration and biosimilar progress. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Aurobindo Pharma analyst review 2027 show?
It shows a record Q2 FY27, with consolidated net profit up about 33% to about ₹1,124 crore. EBITDA rose about 29% to about ₹2,324 crore and margin improved to about 22.3%. Revenue grew about 24% to about ₹10,432 crore.
What is the Aurobindo Pharma share price target 2027 from brokerages?
Geojit set ₹2,111 and Motilal Oswal ₹2,110, both with Buy ratings in November 2026. Prabhudas Lilladher rates it Hold with a target of ₹1,775. The average of the three is about ₹1,999 against a close of ₹1,805.70 on 19 November 2026.
What guidance did Aurobindo Pharma give for FY27?
Management guided for double-digit revenue growth, an EBITDA margin above 21% and absolute EBITDA above ₹8,000 crore. It also said FY28 should be significantly stronger. Full-year Lannett benefits and biosimilars are expected to help.
What new businesses are driving Aurobindo Pharma’s growth?
Biosimilars, the Eugia injectables unit and the Penicillin G plant are the main new drivers. Eugia is expected to cross 500 million dollars in revenue in FY27. US filings for omalizumab, denosumab and bevacizumab biosimilars are planned.
Is Aurobindo Pharma stock fairly valued based on the Aurobindo Pharma analyst review 2027?
The stock trades at about 26 times trailing earnings, below the industry P/E of about 40. Return on equity is about 10% and debt to equity is 0.22. Two of three named brokerages still see upside of about 17%.
Who owns Aurobindo Pharma?
Promoters hold 51.88%, including 33.54% through RPR Sons Advisors. Foreign investors raised their stake to 17.41% from 14.21% over the year. Domestic institutions cut their holding to 24.42% from 27.60%.
What should investors watch after the Aurobindo Pharma analyst review 2027?
Watch EBITDA margin against the 21% guidance and the results of US FDA inspections. Track biosimilar filings and Europe growth. Any target changes after Q3 FY27 results will also matter.